Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.

被引：4

作者：

Osipov, Arsen

Popovic, Aleksandra

Hopkins, Alexander

Frampton, Garrett M.

Albacker, Lee A.

Azad, Nilofer Saba

Laheru, Daniel A.

Zheng, Lei

Jaffee, Elizabeth M.

Yarchoan, Mark

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Balimore, MD USA

[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[3] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[4] Fdn Med Inc, Cambridge, MA USA

[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[6] Johns Hopkins Univ Hosp, Baltimore, MD USA

[7] Johns Hopkins Univ, Baltimore, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.2578

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2578

引用

页数：1

共 50 条

[41] Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4 [J].

Krijgsman, Oscar ;

Kemper, Kristel ;

Boshuizen, Julia ;

Vredevoogd, David W. ;

Rozeman, Elisa A. ;

Molero, Sofia Ibanez ;

de Bruijn, Beaunelle ;

Cornelissen-Steijger, Paulien ;

Shahrabi, Aida ;

Velasco-Herrera, Martin Del Castillo ;

Song, Ji-Ying ;

Ligtenberg, Maarten A. ;

Kluin, Roelof J. C. ;

Kuilman, Thomas ;

Ross-Macdonald, Petra ;

Haanen, John B. A. G. ;

Adams, David J. ;

Blank, Christian U. ;

Peeper, Daniel S. .

CLINICAL CANCER RESEARCH, 2021, 27 (19) :5389-5400

[42] Allograft Rejection Following Immune Checkpoint Inhibition After Renal Transplantation: An In-Depth Analysis of PD-1, PDL-1, and CTLA-4 Checkpoint Inhibitors [J].

Sardar, Sundus ;

Akkari, Abdel-Rauof M. ;

Khan, Mohammad Gul Yousaf ;

Trivedi, Naman ;

Ghahramani, Nasrollah .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 34 (11) :483-483

[43] Immune Checkpoint (PD-1, PD-L1, PD-L2, and CTLA-4) Expression in Plasma Cell Myeloma [J].

Lee, Min Young ;

Park, Chan-jeoung ;

Cho, Young-Uk ;

You, Eunkyoung ;

Jang, Seongsoo ;

Lee, Jung-Hee ;

Hong, Jung Yong ;

Yoon, Dok Hyun ;

Suh, Cheolwon .

BLOOD, 2017, 130

[44] MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways [J].

Touchaei, Arefeh Zabeti ;

Vahidi, Sogand .

CANCER CELL INTERNATIONAL, 2024, 24 (01)

[45] MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways [J].

Arefeh Zabeti Touchaei ;

Sogand Vahidi .

Cancer Cell International, 24

[46] Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB). [J].

Jindal, Tanya ;

Zhu, Xiaolin ;

Zhang, Li ;

Reyes, Kevin R. ;

Deshmukh, Prianka ;

de Kouchkovsky, Ivan ;

Kumar, Vipul ;

Maldonado, Edward ;

Shipp, Chase ;

Kwon, Daniel H. ;

Borno, Hala ;

Bose, Rohit ;

Desai, Arpita ;

Aggarwal, Rahul Raj ;

Porten, Sima P. ;

Small, Eric Jay ;

Fong, Lawrence ;

Chou, Jonathan ;

Friedlander, Terence W. ;

Koshkin, Vadim S. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41

[47] Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer [J].

S A Quezada ;

K S Peggs .

British Journal of Cancer, 2013, 108 :1560-1565

[48] Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4 [J].

Pandey, Pratibha ;

Khan, Fahad ;

Qari, Huda A. ;

Upadhyay, Tarun Kumar ;

Alkhateeb, Abdulhameed F. ;

Oves, Mohammad .

PHARMACEUTICALS, 2022, 15 (03)

[49] Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer [J].

Quezada, S. A. ;

Peggs, K. S. .

BRITISH JOURNAL OF CANCER, 2013, 108 (08) :1560-1565

[50] Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database [J].

Frey, Connor ;

Etminan, Mahyar .

ANTIBODIES, 2024, 13 (03)

← 1 2 3 4 5 →